Disturbed cofactor binding by a novel mutation in UDP-galactose 4 '-epimerase results in a type III galactosemia phenotype at birth

Stephanie Paul, Thomas J. McCorvie, Johannes Zschocke, David Timson

Research output: Contribution to journalArticle

Abstract

UDP-galactose 4′-epimerase (GALE) is an essential enzyme in galactose metabolism and its dysfunction results in type III galactosemia. Herein we report a patient born with abnormal blood galactose levels and reduced GALE activity who was shown to be heterozygous for a c.266C>T missense mutation in the GALE gene, predicted to result in the amino acid exchange p.A89V. Over a period of months, the patient's blood galactose, galactose 1-phosphate and GALE activity levels reverted to normal, encouraging us to investigate this mutation. Structurally Ala89 is a highly conserved residue located close to the binding site of the cofactor, NAD+. Consequentially molecular modelling predicted that this mutation results in steric clashes between the cofactor and valine side chain, and bioinformatic predictions suggested that p.A89V is likely to be less stable than the wild-type. Biochemical studies on the recombinant p.A89V enzyme demonstrated lower activity than the wild type (Km increased by approximately 30-fold; kcat reduced approximately 180-fold), and additionally changes in stability and altered NAD+ binding were observed. Thus, a picture emerges in which this mutation leads to reduced stability, disturbed cofactor binding and subsequently reduced activity. Overall this study suggests that bioinformatics predictions are useful in assessing the effects of newly discovered mutations on enzyme function, but care should be taken in extending predictions to the clinical phenotype especially in cases of heterozygosity. It also raises interesting questions about a dominant negative effect of some GALE missense alleles and potential compensatory mechanisms occurring in people born with clinical chemistry measurements suggesting a diagnosis of galactosemia
Original languageEnglish
Pages (from-to)17297-17301
Number of pages5
JournalRSC Advances
Volume6
Issue number21
DOIs
Publication statusPublished - 3 Feb 2016

Fingerprint

UDPglucose 4-Epimerase
Galactosemias
Galactose
Parturition
Phenotype
Mutation
Computational Biology
NAD
Enzymes
Clinical Chemistry
Valine
Missense Mutation
Alleles
Binding Sites
Amino Acids
galactose epimerase
Genes

Bibliographical note

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence.

Cite this

Paul, Stephanie ; McCorvie, Thomas J. ; Zschocke, Johannes ; Timson, David. / Disturbed cofactor binding by a novel mutation in UDP-galactose 4 '-epimerase results in a type III galactosemia phenotype at birth. In: RSC Advances. 2016 ; Vol. 6, No. 21. pp. 17297-17301.
@article{44afb564d38d44d689b06b53570385e5,
title = "Disturbed cofactor binding by a novel mutation in UDP-galactose 4 '-epimerase results in a type III galactosemia phenotype at birth",
abstract = "UDP-galactose 4′-epimerase (GALE) is an essential enzyme in galactose metabolism and its dysfunction results in type III galactosemia. Herein we report a patient born with abnormal blood galactose levels and reduced GALE activity who was shown to be heterozygous for a c.266C>T missense mutation in the GALE gene, predicted to result in the amino acid exchange p.A89V. Over a period of months, the patient's blood galactose, galactose 1-phosphate and GALE activity levels reverted to normal, encouraging us to investigate this mutation. Structurally Ala89 is a highly conserved residue located close to the binding site of the cofactor, NAD+. Consequentially molecular modelling predicted that this mutation results in steric clashes between the cofactor and valine side chain, and bioinformatic predictions suggested that p.A89V is likely to be less stable than the wild-type. Biochemical studies on the recombinant p.A89V enzyme demonstrated lower activity than the wild type (Km increased by approximately 30-fold; kcat reduced approximately 180-fold), and additionally changes in stability and altered NAD+ binding were observed. Thus, a picture emerges in which this mutation leads to reduced stability, disturbed cofactor binding and subsequently reduced activity. Overall this study suggests that bioinformatics predictions are useful in assessing the effects of newly discovered mutations on enzyme function, but care should be taken in extending predictions to the clinical phenotype especially in cases of heterozygosity. It also raises interesting questions about a dominant negative effect of some GALE missense alleles and potential compensatory mechanisms occurring in people born with clinical chemistry measurements suggesting a diagnosis of galactosemia",
author = "Stephanie Paul and McCorvie, {Thomas J.} and Johannes Zschocke and David Timson",
note = "This article is licensed under a Creative Commons Attribution 3.0 Unported Licence.",
year = "2016",
month = "2",
day = "3",
doi = "10.1039/C6RA00306K",
language = "English",
volume = "6",
pages = "17297--17301",
journal = "RSC Advances",
issn = "2046-2069",
number = "21",

}

Disturbed cofactor binding by a novel mutation in UDP-galactose 4 '-epimerase results in a type III galactosemia phenotype at birth. / Paul, Stephanie; McCorvie, Thomas J.; Zschocke, Johannes; Timson, David.

In: RSC Advances, Vol. 6, No. 21, 03.02.2016, p. 17297-17301.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Disturbed cofactor binding by a novel mutation in UDP-galactose 4 '-epimerase results in a type III galactosemia phenotype at birth

AU - Paul, Stephanie

AU - McCorvie, Thomas J.

AU - Zschocke, Johannes

AU - Timson, David

N1 - This article is licensed under a Creative Commons Attribution 3.0 Unported Licence.

PY - 2016/2/3

Y1 - 2016/2/3

N2 - UDP-galactose 4′-epimerase (GALE) is an essential enzyme in galactose metabolism and its dysfunction results in type III galactosemia. Herein we report a patient born with abnormal blood galactose levels and reduced GALE activity who was shown to be heterozygous for a c.266C>T missense mutation in the GALE gene, predicted to result in the amino acid exchange p.A89V. Over a period of months, the patient's blood galactose, galactose 1-phosphate and GALE activity levels reverted to normal, encouraging us to investigate this mutation. Structurally Ala89 is a highly conserved residue located close to the binding site of the cofactor, NAD+. Consequentially molecular modelling predicted that this mutation results in steric clashes between the cofactor and valine side chain, and bioinformatic predictions suggested that p.A89V is likely to be less stable than the wild-type. Biochemical studies on the recombinant p.A89V enzyme demonstrated lower activity than the wild type (Km increased by approximately 30-fold; kcat reduced approximately 180-fold), and additionally changes in stability and altered NAD+ binding were observed. Thus, a picture emerges in which this mutation leads to reduced stability, disturbed cofactor binding and subsequently reduced activity. Overall this study suggests that bioinformatics predictions are useful in assessing the effects of newly discovered mutations on enzyme function, but care should be taken in extending predictions to the clinical phenotype especially in cases of heterozygosity. It also raises interesting questions about a dominant negative effect of some GALE missense alleles and potential compensatory mechanisms occurring in people born with clinical chemistry measurements suggesting a diagnosis of galactosemia

AB - UDP-galactose 4′-epimerase (GALE) is an essential enzyme in galactose metabolism and its dysfunction results in type III galactosemia. Herein we report a patient born with abnormal blood galactose levels and reduced GALE activity who was shown to be heterozygous for a c.266C>T missense mutation in the GALE gene, predicted to result in the amino acid exchange p.A89V. Over a period of months, the patient's blood galactose, galactose 1-phosphate and GALE activity levels reverted to normal, encouraging us to investigate this mutation. Structurally Ala89 is a highly conserved residue located close to the binding site of the cofactor, NAD+. Consequentially molecular modelling predicted that this mutation results in steric clashes between the cofactor and valine side chain, and bioinformatic predictions suggested that p.A89V is likely to be less stable than the wild-type. Biochemical studies on the recombinant p.A89V enzyme demonstrated lower activity than the wild type (Km increased by approximately 30-fold; kcat reduced approximately 180-fold), and additionally changes in stability and altered NAD+ binding were observed. Thus, a picture emerges in which this mutation leads to reduced stability, disturbed cofactor binding and subsequently reduced activity. Overall this study suggests that bioinformatics predictions are useful in assessing the effects of newly discovered mutations on enzyme function, but care should be taken in extending predictions to the clinical phenotype especially in cases of heterozygosity. It also raises interesting questions about a dominant negative effect of some GALE missense alleles and potential compensatory mechanisms occurring in people born with clinical chemistry measurements suggesting a diagnosis of galactosemia

U2 - 10.1039/C6RA00306K

DO - 10.1039/C6RA00306K

M3 - Article

VL - 6

SP - 17297

EP - 17301

JO - RSC Advances

JF - RSC Advances

SN - 2046-2069

IS - 21

ER -